The National Marrow Donor Program 20 years of unrelated donor hematopoietic cell transplantation

被引:65
作者
Ballen, Karen K. [1 ]
King, Roberta J. [2 ]
Chitphakdithai, Pintip [2 ]
Bolan, Charles D., Jr. [3 ]
Agura, Edward [4 ]
Hartzman, Robert J. [5 ]
Kernan, Nancy A. [6 ]
机构
[1] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[2] Natl Marrow Donor Program, Minneapolis, MN USA
[3] NHLBI, Hematol Branch, NIH, Rockville, MD USA
[4] Baylor Univ, Med Ctr, Houston, TX 77030 USA
[5] USN, Med Res Ctr, CW Bill Young Dept, Def Marrow Donor Program, Rockville, MD USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
National Marrow Donor Program; NMDP; unrelated donor; stem cell transplant; transplantation;
D O I
10.1016/j.bbmt.2008.05.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the 20 years since the National Marrow Donor Program (NMDP) facilitated the first unrelated donor transplant, the organization has grown to include almost 7 million donors, and has facilitated over 30,000 transplants on 6 continents. This remarkable accomplishment has been facilitated by the efforts of over 600 employees, and an extensive international network including 171 transplant centers, 73 donor centers, 24 cord blood banks, 97 bone marrow collection centers, 91 apheresis centers, 26 HLA typing laboratories, and 26 Cooperative Registries. In this article, we review the history of the NMDP, and cite the major trends in patient demographics, graft sources, and conditioning regimens over the last 20 years. (C) 2008 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:2 / 7
页数:6
相关论文
共 16 条
  • [11] Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    McSweeney, PA
    Niederwieser, D
    Shizuru, JA
    Sandmaier, BM
    Molina, AJ
    Maloney, DG
    Chauncey, TR
    Gooley, TA
    Hegenbart, U
    Nash, RA
    Radich, J
    Wagner, JL
    Minor, S
    Appelbaum, FR
    Bensinger, WI
    Bryant, E
    Flowers, MED
    Georges, GE
    Grumet, FC
    Kiem, HP
    Torok-Storb, B
    Yu, G
    Blume, KG
    Storb, RF
    [J]. BLOOD, 2001, 97 (11) : 3390 - 3400
  • [12] Mori M, 1996, Biol Blood Marrow Transplant, V2, P134
  • [13] Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
    Niederwieser, D
    Maris, M
    Shizuru, JA
    Petersdorf, E
    Hegenbart, U
    Sandmaier, BM
    Maloney, DG
    Storer, B
    Lange, T
    Chauncey, T
    Deininger, M
    Pönisch, W
    Anasetti, C
    Woolfrey, A
    Little, MT
    Blume, KG
    McSweeney, PA
    Storb, RF
    [J]. BLOOD, 2003, 101 (04) : 1620 - 1629
  • [14] RIES LAG, 2004, SEER SURVEILLANCE EP
  • [15] HLA gene and haplotype frequencies in bone marrow donors worldwide registries
    Schipper, RF
    DAmaro, J
    Bakker, JT
    vanRood, JJ
    Oudshoorn, M
    [J]. HUMAN IMMUNOLOGY, 1997, 52 (01) : 54 - 71
  • [16] Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
    Slavin, S
    Nagler, A
    Naparstek, E
    Kapelushnik, Y
    Aker, M
    Cividalli, G
    Varadi, G
    Kirschbaum, M
    Ackerstein, A
    Samuel, S
    Amar, A
    Brautbar, C
    Ben-Tal, O
    Eldor, A
    Or, R
    [J]. BLOOD, 1998, 91 (03) : 756 - 763